Has Michael Swank, MD received payments from drug or device companies?

Yes. Drug and device makers reported $563,022 in general payments to Michael Swank, MD across 79 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Swank, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Swank, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Swank, MD

Orthopaedic Surgery · Cincinnati, OHNPI 1982641999

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $531,825 of the $563,022 with a category attached, or 94.5%. Smith+Nephew accounts for 94.1% of it on its own, with 10 other manufacturers making up the rest. Among orthopaedic surgery clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$563,022in general payments, 2019–2025

Across 79 payments — averaging $7126.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Smith+Nephew$530K
Depuy Synthes Products, Inc.$17K
Medical Device Business Services, Inc.$11K
Restor3d, Inc.$4K
Johnson & Johnson$355
Baxter Healthcare$141
plus $347 from 5 others

$440,750in research payments, 2019–2025

Across 139 payments — averaging $3170.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medical Device Business Services, Inc.$261K
Smith+Nephew$157K
Zimmer Biomet$23K

$2,099in ownership & investment interests, 2019–2025

Across 1 payment — averaging $2099.45 each. An ownership or investment interest held by the physician or an immediate family member.

Restor3d, Inc.$2K

What the payments were for

Royalty or licence$531,82594%
Consulting fees$28,3495%
Travel & lodging$1,3840%
Food & beverage$1,4640%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Smith+Nephew	31	$529,999
Depuy Synthes Products, Inc.	6	$17,479
Medical Device Business Services, Inc.	10	$10,995
Restor3d, Inc.	5	$3,706
Johnson & Johnson	14	$355
Baxter Healthcare	6	$141
Orthalign Inc	2	$139
Heron Therapeutics, Inc.	1	$123
Zimmer Biomet	2	$42
Vertex	1	$26
Stryker	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NAVIO$496,524
REAL INTELLIGENCE$193,516
Navio Surgical System$33,309
Velys$11,550
VELYS Hip Navigation$8,663
Oxinium Hips$8,040
POLARSTEM$8,040
R3$8,040
TRUMATCH$7,962
ATTUNE$2,363
CORI$144
Zynrelef$123
ORTHALIGN PLUS$114

How this compares

$563,022 in reported general payments places this provider in the 95th percentile of 794 orthopaedic surgery providers in Ohio.

See all orthopaedic surgery providers in Ohio →

Medicare billing

Part B allowed, 2024

$418,156

Medicare patients

593

Services billed

1,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	149	$1,195
Meloxicam	548	$1,127
Celecoxib	18	$330
Amoxicillin	167	$197
Oxycodone Hcl	37	$197
Methylprednisolone	21	$134
Prednisone	53	$122
Duloxetine Hcl	11	$91
Clindamycin Hcl	36	$65

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Cincinnati

Michael ArchdeaconCincinnati$2.3M
Paul FavoritoCincinnati$961K
Suresh NayakCincinnati$536K
Jonathon SpanyerCincinnati$193K
John WyrickCincinnati$169K
Robert RolfCincinnati$128K
Todd KelleyCincinnati$71K
Reuben GobezieCleveland$12M
Gregory BerletWorthington$9.6M
Wael BarsoumCleveland$8.9M

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →